SPC
NVCR icon

Sigma Planning Corp’s NovoCure NVCR Stock Holding History

Sigma Planning Corp’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,885
Closed -$361K – 932
2018
Q3 		$361K Sell
6,885
-15
-0.2% -$597 0.02% 613
2018
Q2 		$216K Buy
+6,900
New +$192K 0.01% 800

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Sigma Planning Corp's NVCR Position: Q4 2018 in Review

Sigma Planning Corp sold out of NovoCure (NVCR) in Q4 2018, closing a stake of 6,885 shares — an estimated $361K sold.

Sigma Planning Corp first reported a position in NVCR in Q2 2018 and held it in 2 quarters. The position peaked at $361K in Q3 2018. 166 funds tracked by Wall St. Rank hold NVCR as of Q4 2018.

  • Sigma Planning Corp reported no remaining NovoCure position as of Q4 2018 after selling out during the quarter.
  • Sigma Planning Corp sold 6,885 NovoCure shares in Q4 2018, an estimated $361K.
  • Sigma Planning Corp first reported a position in NovoCure in Q2 2018 and held it in 2 quarters.
  • Sigma Planning Corp's NovoCure position peaked at $361K in Q3 2018.
  • 166 funds tracked by Wall St. Rank held NovoCure as of Q4 2018.

Based on Sigma Planning Corp's 13F filing for Q4 2018, filed 31 Jan 2019.